Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: An open-label trial

Keyphrases

• Open-label Trial 100%
• Hereditary Angioedema 100%
• C1 Inhibitor 100%
• C1 Esterase Inhibitor 100%
• Acute Attack 100%
• Angioedema Attack 50%
• Short-term Treatment 25%
• Median Time 12%
• Laboratory Testing 12%
• Edema 12%
• Gene mutation 12%
• Recurrent Episodes 12%
• Life-threatening 12%
• Response Rate 12%
• Rare Diseases 12%
• First Dose 12%
• Repeated Use 12%
• Initial Attack 12%
• Vital Sign Measurement 12%
• Adverse Event Reporting 12%
• Medication Response 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Open-Label Trial 100%
• Complement Component C1s Inhibitor 100%
• Angioneurotic Edema 100%
• Isoniazid 100%
• Adverse Event 14%
• Edema 14%
• Rare Disease 14%